4.7 Article

Glutamate neurocircuitry: theoretical underpinnings in schizophrenia

期刊

FRONTIERS IN PHARMACOLOGY
卷 3, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2012.00195

关键词

schizophrenia; dopamine hypothesis; glutamate hypothesis; NMDA receptor

资金

  1. Astra Zeneca
  2. Biomarin
  3. Dainippon Sumitomo/Sepracor/Sunovion
  4. Eli Lilly
  5. Forest
  6. Genomind
  7. Merck/Schering Plough
  8. PamLabs
  9. Pfizer
  10. PGxHealth
  11. Servier
  12. Shire
  13. Torrent
  14. Trovis

向作者/读者索取更多资源

The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA Receptor Hypofunctioning Hypothesis of Schizophrenia. The latter hypothesis may actually be the starting point in neuronal pathways that ultimately modifies dopamine pathways involved in generating both positive and negative symptoms of schizophrenia postulated by the former hypothesis. The authors suggest that even this latter, NMDA receptor-based, hypothesis is likely too narrow and offer a review of typical glutamate and dopamine-based neurocircuitry, propose genetic vulnerabilities impacting glutamate neurocircuitry, and provide a broad interpretation of a possible etiology of schizophrenia. In conclusion, there is a brief review of potential schizophrenia treatments that rely on the etiologic theory provided in the body of the paper.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据